TrialSignal
Clinical trial intelligence report
A Post-Market, Prospective, Multi-Center, Single-Arm Clinical Investigation of Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT02720042
Status
COMPLETED
Phase
Post-Market
Sponsor
C. R. Bard
Executive brief
Investment-Ready Snapshot
C. R. Bard conducted a clinical trial to assess the safety and performance of Phasix™ Mesh in treating VHWG Grade 3 midline hernias. The study enrolled 84 patients across 12 sites in Europe, with a focus on long-term outcomes over 24 months.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02720042
Indication
Hernia
Modality
medical device
Target
Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair
Intervention
Phasix™ Mesh
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.